No licensed hantavirus vaccine exists, and leading candidates remain in preclinical stages or early Phase 1 trials as of May 2026, supporting the 89.5% market-implied probability of no approval this year. Recent outbreaks, including a confirmed cluster linked to a cruise ship, have prompted renewed research interest and modest funding discussions, yet DNA-based and mRNA platforms targeting the Gn-Gc glycoprotein still require extensive safety and efficacy testing. Historical timelines for similar emerging-virus vaccines show that advancing from current data—where neutralizing antibodies appear in limited human studies—to full regulatory clearance typically spans multiple years without accelerated programs comparable to Operation Warp Speed. Ongoing model refinements and surveillance updates from agencies like the CDC and WHO are unlikely to compress this schedule before December 31.
Polymarket ডেটা রেফারেন্স করে পরীক্ষামূলক AI-জেনারেটেড সারাংশ। এটি ট্রেডিং পরামর্শ নয় এবং এই মার্কেট কীভাবে রেজলভ হয় তাতে কোনো ভূমিকা রাখে না। · আপডেটেডHantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
$89,055 Vol.
$89,055 Vol.
Dec 31, 2026
$89,055 Vol.
$89,055 Vol.
Dec 31, 2026
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.No licensed hantavirus vaccine exists, and leading candidates remain in preclinical stages or early Phase 1 trials as of May 2026, supporting the 89.5% market-implied probability of no approval this year. Recent outbreaks, including a confirmed cluster linked to a cruise ship, have prompted renewed research interest and modest funding discussions, yet DNA-based and mRNA platforms targeting the Gn-Gc glycoprotein still require extensive safety and efficacy testing. Historical timelines for similar emerging-virus vaccines show that advancing from current data—where neutralizing antibodies appear in limited human studies—to full regulatory clearance typically spans multiple years without accelerated programs comparable to Operation Warp Speed. Ongoing model refinements and surveillance updates from agencies like the CDC and WHO are unlikely to compress this schedule before December 31.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
মার্কেট ওপেন হয়েছে: May 4, 2026, 10:39 AM ET
ভলিউম
$89,055শেষ তারিখ
Dec 31, 2026মার্কেট ওপেন হয়েছে
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.No licensed hantavirus vaccine exists, and leading candidates remain in preclinical stages or early Phase 1 trials as of May 2026, supporting the 89.5% market-implied probability of no approval this year. Recent outbreaks, including a confirmed cluster linked to a cruise ship, have prompted renewed research interest and modest funding discussions, yet DNA-based and mRNA platforms targeting the Gn-Gc glycoprotein still require extensive safety and efficacy testing. Historical timelines for similar emerging-virus vaccines show that advancing from current data—where neutralizing antibodies appear in limited human studies—to full regulatory clearance typically spans multiple years without accelerated programs comparable to Operation Warp Speed. Ongoing model refinements and surveillance updates from agencies like the CDC and WHO are unlikely to compress this schedule before December 31.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
ভলিউম
$89,065শেষ তারিখ
Dec 31, 2026মার্কেট ওপেন হয়েছে
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...No licensed hantavirus vaccine exists, and leading candidates remain in preclinical stages or early Phase 1 trials as of May 2026, supporting the 89.5% market-implied probability of no approval this year. Recent outbreaks, including a confirmed cluster linked to a cruise ship, have prompted renewed research interest and modest funding discussions, yet DNA-based and mRNA platforms targeting the Gn-Gc glycoprotein still require extensive safety and efficacy testing. Historical timelines for similar emerging-virus vaccines show that advancing from current data—where neutralizing antibodies appear in limited human studies—to full regulatory clearance typically spans multiple years without accelerated programs comparable to Operation Warp Speed. Ongoing model refinements and surveillance updates from agencies like the CDC and WHO are unlikely to compress this schedule before December 31.
Polymarket ডেটা রেফারেন্স করে পরীক্ষামূলক AI-জেনারেটেড সারাংশ। এটি ট্রেডিং পরামর্শ নয় এবং এই মার্কেট কীভাবে রেজলভ হয় তাতে কোনো ভূমিকা রাখে না। · আপডেটেড
বাহ্যিক লিংক থেকে সাবধান।
বাহ্যিক লিংক থেকে সাবধান।
সচরাচর জিজ্ঞাসা